Joseph Fortunak - Immune Therapeutics VP
IMUNDelisted Stock | USD 0.06 0 4.76% |
VP
Dr. Joseph M. Fortunak is Vice President of Global Research and Development and Chemical Development of the Company. He graduated from the University of WisconsinMadison with a PhD in Organic Chemistry. After spending time holding a postdoctoral position at Cambridge University, he spent over 20 years in the pharmaceutical industry, most recently as Director and Head of Global Process Research and Development at Abbott Laboratories, from 2000 to 2004. Before taking the position at Abbott Laboratories, from 1983 to 1993, Dr. Fortunak worked as Associate Senior Research Investigator, Senior Research Investigator, and Assistant Director for Smith Kline Beechman, and from 1993 to 2000 was the Associate Director, Director, Senior Director, and Executive Director of DuPont Pharmaceutical Company. In 2004, Dr. Fortunak assumed the position of Associate Professor of Chemistry and Pharmaceutical Sciences at Howard University in Washington, D.C., with a goal of developing an international program for cGMP practices worldwide since 2013.
Age | 68 |
Tenure | 11 years |
Professional Marks | CPA |
Phone | 888 613 8802 |
Web | https://www.immunetherapeutics.com |
Immune Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4526) % which means that it has lost $0.4526 on every $100 spent on assets. This is way below average. Immune Therapeutics' management efficiency ratios could be used to measure how well Immune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.08 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immune Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Immune Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immune Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immune to invest in growth at high rates of return. When we think about Immune Therapeutics' use of debt, we should always consider it together with cash and equity.
Immune Therapeutics, Inc. does not have significant operations. Immune Therapeutics, Inc. is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Immune Therapeutics [IMUN] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Management Performance
Return On Asset | -0.45 |
Immune Therapeutics Leadership Team
Elected by the shareholders, the Immune Therapeutics' board of directors comprises two types of representatives: Immune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immune. The board's role is to monitor Immune Therapeutics' management team and ensure that shareholders' interests are well served. Immune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kevin Phelps, Director | ||
Peter Aronstam, CFO | ||
Christopher Pearce, COO, Director | ||
FMedSci FRACP, Chief RD | ||
Jack Brewer, Director | ||
Glen MBA, Chief Officer | ||
Clifford Selsky, Independent Director | ||
Nicholas Plotnikoff, Non-Executive Chairman of the Board | ||
Fengping Shan, Chief Science Officer | ||
Noreen Griffin, Founder, Chairman and CEO | ||
Edward Teraskiewicz, Independent Director | ||
Joseph Fortunak, VP of Global RandD and Chemical Devel. and Member of Advisory Board | ||
Paul Akin, Independent Director | ||
Rudy Williams, COO | ||
Kelly Wilson, Interim Pres |
Immune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | -0.45 | |||
Current Valuation | 83.25 M | |||
Shares Outstanding | 82.76 M | |||
Shares Owned By Insiders | 29.51 % | |||
Price To Earning | 333.33 X | |||
Price To Sales | 161.50 X | |||
Gross Profit | 65.83 K | |||
EBITDA | 3.8 M | |||
Net Income | 3.59 M | |||
Cash And Equivalents | 271.53 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |